Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Crawford Readies Himself For "Intense Week" Of Congressional Hearings

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA Acting Commissioner Lester Crawford will appear in front of four congressional committees this week in what amounts to "the most intense week of congressional hearings that we have had in FDA's history," he said

You may also be interested in...



New Labeling Rule Will Require Rx Warnings To Appear At Beginning Of DTC Ads

The proposed physician labeling rule will by published by the end of November, FDA Acting Commissioner Crawford says. The rule is designed to provide more useful information to physicians and patients.

FDA's Cure For The Flu: Orphan Drug-Like Incentives, Tissue-Based Production

The agency plans to request congressional action on influenza vaccine incentives during three hearings on the flu vaccine shortage. FDA, in cooperation with U.K. regulatory officials, will determine in January whether Chiron will be able to manufacture Fluvirin at the company’s Liverpool facility for the 2005-06 flu season.

New Labeling Rule Will Require Rx Warnings To Appear At Beginning Of DTC Ads

The proposed physician labeling rule will by published by the end of November, FDA Acting Commissioner Crawford says. The rule is designed to provide more useful information to physicians and patients.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel